Biological characterization of ADAM22 variants reveals the importance of a disintegrin domain sequence in cell surface expression

• Published in: Journal of receptors and signal transduction Vol. 30; no. 2; p. 72
• Main Authors: Sagane, Koji, Sugimoto, Hachiro, Akaike, Akinori
• Format: Journal Article
• Language: English
• Published: England 01.04.2010
• Subjects: ADAM Proteins - metabolism; Cell Membrane - metabolism; Disintegrins - chemistry; Disintegrins - metabolism; Enzyme-Linked Immunosorbent Assay; Extracellular Matrix Proteins - genetics; Extracellular Matrix Proteins - metabolism; Fluorescent Antibody Technique; HeLa Cells - ultrastructure; Humans; Immunoblotting; Immunoprecipitation; Mutation - genetics; Nerve Tissue Proteins - metabolism; Protein Binding; Protein Processing, Post-Translational
• ISSN: 1532-4281
• DOI: 10.3109/10799891003614790

ADAM metallopeptidase domain 22 (ADAM22) is a neuronal membrane-spanning protein that is a potential receptor for leucine-rich, glioma-inactivated 1 (LGI1), and leucine-rich repeat LGI family, member 4 (LGI4). Several lines of study have shown a direct interaction between ADAM22 and LGI1, a mutation which is responsible for inherited epilepsy in humans. Both ADAM22-deficient mice and claw paw mice, congenitally deficient in LGI4, show hypomyelination in the peripheral nerves, suggesting that these molecules are involved in myelination processes. These findings mark ADAM22 as a potential target molecule for epilepsy or demyelination diseases. To investigate the relationship between ADAM22 mutation and its biological character, we designed and examined several ADAM22 variants. We discovered that the ADAM22 P81R variant, the most common polymorphic variation, works as well as the wild-type ADAM22. We also showed that mutations in the disintegrin domain cause a marked decrease in the processing of ADAM22 preproteins, and result in reduced LGI4-binding abilities. Our findings provide valuable information for mutation screening of the ADAM22 gene in patients suffering from epilepsy or demyelinating diseases.